{"id":"W2135530224","doi":"10.1200/jco.2014.57.1513","title":"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; Taxane; Breast cancer; Placebo; Chemotherapy; Progression-free survival; Cancer; Randomized controlled trial; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06048642,0.0002202676,0.005796141,0.0003519605,0.00004490346,0.00001030709,0.0003822936,0.0002801,0.0006346181],"category_scores_gemma":[0.0560234,0.000123692,0.001107335,0.0003879066,0.0004563042,0.00008785962,0.00006305752,0.001351736,0.000003563495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004374273,"about_ca_system_score_gemma":0.004580464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002534518,"about_ca_topic_score_gemma":0.000363076,"domain_scores_codex":[0.9849678,0.005427701,0.00752074,0.0003060033,0.001391652,0.0003860522],"domain_scores_gemma":[0.9553736,0.03720142,0.005337568,0.0004337223,0.001298085,0.0003555851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7939595,0.003244132,0.00005136564,0.00008870941,0.0007396224,0.00002647677,0.0003328868,0.0004133329,0.0006054339,0.00001120474,0.003051179,0.1974761],"study_design_scores_gemma":[0.9504265,0.03569443,0.0009222596,0.0006341785,0.0008725091,0.00007492074,0.00005789293,0.007953767,0.0001639769,0.0003044512,0.002799246,0.00009584799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9504351,0.0004403009,0.0007865286,0.04094981,0.001045794,0.005105356,0.00008420322,0.000007218402,0.001145657],"genre_scores_gemma":[0.9909129,0.001093344,0.002710428,0.002774045,0.001977613,0.0002523033,0.000009661021,0.00003282902,0.0002368683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1973803,"threshold_uncertainty_score":0.967427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1991386133547665,"score_gpt":0.5626661216359241,"score_spread":0.3635275082811576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}